Form 4: Soleno Therapeutics Merger: Executive Ownership Changes

Soleno Therapeutics reports on executive stock option and RSU conversions following a merger, detailing cash payouts for vested and unvested equity.

Summary

• Manher Joshi, Chief Development Officer at Soleno Therapeutics Inc., reported changes in beneficial ownership on May 18, 2026.
• This filing is related to the merger between Soleno Therapeutics, Inc., Neocrine Biosciences, Inc. (Parent), and Sigma Merger Sub, Inc. (Merger Sub).
• In connection with the merger, all outstanding shares of Soleno Therapeutics' Common Stock were converted into the right to receive $53.00 in cash per share.
• Previously reported restricted stock units (RSUs) totaling 20,171 were cancelled and converted into the right to receive the merger consideration.
• Stock options were also cancelled and converted into cash payments. This included an option for 72,321 shares with an exercise price of $46.31, and another for 4,700 shares with an exercise price of $43.65.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on the completion of a merger and the resulting cash conversion of equity, rather than new operational or financial performance.

Positives

• The merger provides a cash payout of $53.00 per share for all outstanding common stock.
• Vested and unvested RSUs were converted into the right to receive the merger consideration, indicating value realization for equity holders.
• Stock options were converted into cash payments, representing the difference between the merger consideration and the exercise price.

Negatives

• All outstanding shares of common stock were converted into cash, meaning no continued equity ownership in the merged entity for former Soleno shareholders.
• RSUs and stock options were cancelled and converted into cash, eliminating future equity participation for the reporting person and other holders.

Risks

• The filing does not explicitly mention any risks associated with the merger itself, but the conversion of equity to cash implies a loss of potential upside from future growth of the combined entity.

Future Outlook

The filing primarily details the completion of a merger and the conversion of equity into cash. There are no explicit forward-looking statements or guidance provided regarding the future operations of the combined entity.

Management Comments

• Manher Joshi, Chief Development Officer, is the reporting person for these transactions.
• The filing details the conversion of RSUs and stock options into cash payments as per the merger agreement.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a common outcome in the biotechnology and pharmaceutical sectors where mergers and acquisitions are frequent, often resulting in the conversion of employee equity into cash payouts for shareholders of the acquired company.

Comparison to Industry Standards

• In the context of biotech M&A, a cash-out of $53.00 per share for Soleno Therapeutics is a specific valuation determined by the merger agreement between Soleno, Neocrine Biosciences, and Sigma Merger Sub.
• The conversion of stock options and RSUs into cash is standard practice in such transactions, with the payout amount calculated based on the difference between the merger consideration and the strike price (for options) or the value of the award (for RSUs).

Stakeholder Impact

• Shareholders of Soleno Therapeutics will receive $53.00 in cash for each share of common stock they held.
• Employees and executives holding RSUs and stock options will receive cash payouts based on the terms of the merger agreement.
• The company will cease to be a publicly traded entity as it becomes a wholly owned subsidiary.

Next Steps

• The merger has been completed, with Soleno Therapeutics becoming a wholly owned subsidiary of Parent.
• All outstanding equity (common stock, RSUs, stock options) has been converted into cash payments.

Key Dates

Keywords

Soleno Therapeutics, Merger, Form 4, SEC Filing, Stock Options, RSUs, Beneficial Ownership, Manher Joshi, Neocrine Biosciences, Sigma Merger Sub